The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
Proton Pump Inhibitors (PPIs): Very rare reports of subacute erythematosus (SCLE)
Donepezil: Reports of Rhabdomyolysis
Adverse Reaction Reporting during 2014